MX2012002529A - Agente terapeutico para trastornos de ansiedad. - Google Patents

Agente terapeutico para trastornos de ansiedad.

Info

Publication number
MX2012002529A
MX2012002529A MX2012002529A MX2012002529A MX2012002529A MX 2012002529 A MX2012002529 A MX 2012002529A MX 2012002529 A MX2012002529 A MX 2012002529A MX 2012002529 A MX2012002529 A MX 2012002529A MX 2012002529 A MX2012002529 A MX 2012002529A
Authority
MX
Mexico
Prior art keywords
anxiety disorders
therapeutic agent
therapeutic
pharmaceutically acceptable
general formula
Prior art date
Application number
MX2012002529A
Other languages
English (en)
Inventor
Junya Kase
Tomoyuki Kanda
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649340&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of MX2012002529A publication Critical patent/MX2012002529A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Se proporciona un agente para el tratamiento y/o profilaxis de un trastorno de ansiedad que comprende, como un ingrediente activo, un derivado de tiazol representado por la fórmula (I) en donde R1 representa arilo o similar, y R2 representa piridilo o similar, o una de sus sales farmacéuticamente aceptables, y similar.
MX2012002529A 2009-09-02 2010-09-02 Agente terapeutico para trastornos de ansiedad. MX2012002529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009202894 2009-09-02
PCT/JP2010/064989 WO2011027806A1 (ja) 2009-09-02 2010-09-02 不安障害治療剤

Publications (1)

Publication Number Publication Date
MX2012002529A true MX2012002529A (es) 2012-04-11

Family

ID=43649340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002529A MX2012002529A (es) 2009-09-02 2010-09-02 Agente terapeutico para trastornos de ansiedad.

Country Status (31)

Country Link
US (1) US20120172362A1 (es)
EP (1) EP2474544B1 (es)
JP (1) JP5663485B2 (es)
KR (2) KR20120047311A (es)
CN (1) CN102482271A (es)
AU (1) AU2010290424C1 (es)
BR (1) BR112012004850A2 (es)
CA (1) CA2772922C (es)
CL (1) CL2012000533A1 (es)
CY (1) CY1119483T1 (es)
DK (1) DK2474544T3 (es)
DO (1) DOP2012000056A (es)
EA (1) EA023728B1 (es)
ES (1) ES2643840T3 (es)
GE (1) GEP20156225B (es)
HR (1) HRP20171418T1 (es)
HU (1) HUE036543T2 (es)
IL (1) IL218320A (es)
LT (1) LT2474544T (es)
MA (1) MA33619B1 (es)
ME (1) ME02877B (es)
MX (1) MX2012002529A (es)
NZ (1) NZ598754A (es)
PL (1) PL2474544T3 (es)
PT (1) PT2474544T (es)
RS (1) RS56401B1 (es)
SI (1) SI2474544T1 (es)
TN (1) TN2012000093A1 (es)
UA (1) UA113383C2 (es)
WO (1) WO2011027806A1 (es)
ZA (1) ZA201202347B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
MA41090A (fr) * 2014-12-03 2017-10-10 H Lundbeck As Antagoniste de a2a faiblement dosé pour le traitement du tdah et de la maladie de parkinson
JOP20200093A1 (ar) 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
JO3544B1 (ar) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331843T2 (de) 1992-07-08 2002-09-26 Kyowa Hakko Kogyo Kk Xanthine-Derivate als Antidepressiva
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
WO2000069464A1 (fr) * 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Nouvelle utilisation
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
ATE481101T1 (de) 2003-06-10 2010-10-15 Kyowa Hakko Kirin Co Ltd Verfahren zur behandlung von angstzuständen
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
US20100280023A1 (en) * 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
PT1921077T (pt) * 2005-08-02 2017-10-26 Kyowa Hakko Kirin Co Ltd Agente para tratar e/ou prevenir distúrbio do sono
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою

Also Published As

Publication number Publication date
ES2643840T3 (es) 2017-11-24
CL2012000533A1 (es) 2012-09-14
EA023728B1 (ru) 2016-07-29
KR20170044768A (ko) 2017-04-25
IL218320A0 (en) 2012-04-30
BR112012004850A2 (pt) 2020-06-23
AU2010290424B2 (en) 2015-11-05
RS56401B1 (sr) 2018-01-31
ZA201202347B (en) 2015-11-25
DK2474544T3 (en) 2017-10-02
MA33619B1 (fr) 2012-09-01
CA2772922C (en) 2017-11-21
DOP2012000056A (es) 2012-06-30
JP5663485B2 (ja) 2015-02-04
HUE036543T2 (hu) 2018-07-30
WO2011027806A1 (ja) 2011-03-10
HRP20171418T1 (hr) 2017-11-03
JPWO2011027806A1 (ja) 2013-02-04
EP2474544A4 (en) 2013-01-23
PL2474544T3 (pl) 2017-12-29
KR20120047311A (ko) 2012-05-11
NZ598754A (en) 2014-08-29
PT2474544T (pt) 2017-10-03
IL218320A (en) 2016-06-30
LT2474544T (lt) 2017-10-25
AU2010290424A1 (en) 2012-04-19
CN102482271A (zh) 2012-05-30
TN2012000093A1 (en) 2013-09-19
EA201270360A1 (ru) 2012-09-28
ME02877B (me) 2018-04-20
GEP20156225B (en) 2015-01-26
UA113383C2 (xx) 2017-01-25
US20120172362A1 (en) 2012-07-05
EP2474544B1 (en) 2017-07-12
AU2010290424C1 (en) 2016-02-18
EP2474544A1 (en) 2012-07-11
CY1119483T1 (el) 2018-03-07
SI2474544T1 (sl) 2017-11-30
CA2772922A1 (en) 2011-10-03

Similar Documents

Publication Publication Date Title
MX2012002528A (es) Agente terapeutico para trastornos del estado de animo.
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
TW200728307A (en) Novel spirochromanone derivatives
MX2012000414A (es) Derivados piridin-4-ilo.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2010004232A (es) Compuesto de indolina de pirimidilo.
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
MX2011011269A (es) Agente terapeutico para trastornos de la motilidad.
AU2010243044A8 (en) Carbinol compound having heterocyclic linker
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
MY160392A (en) Triptolide prodrugs
WO2008131946A3 (de) Substituierte amid-derivate
WO2012140596A8 (en) Glycoside derivatives and uses thereof
CY1119483T1 (el) Θεραπευτικος παραγων για τις αγχωδεις διαταραχες
MX345264B (es) Derivado de azol.
PH12015501056A1 (en) 2-pyridone compound
MX2012012410A (es) Agente terapeutico y agente preventivo para enfermedad de alzheimer.
MX355654B (es) Derivado de paroxetina.
WO2012125663A3 (en) Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists
TN2012000084A1 (en) Fused heterocyclic ring derivative and use thereof
TN2012000617A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof
WO2012169863A3 (en) 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof

Legal Events

Date Code Title Description
FG Grant or registration